Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.
作者信息
Nykaza Ian, Dusza Stephen W, Rosenberg Jonathan E, Iyer Gopa, Feld Emily, Chandarlapaty Sarat, Jhaveri Komal, Lacuna Kristine, Gajria Devika, Bielawa Megan, Markova Alina, Gordon Allison
机构信息
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.
出版信息
JAMA Dermatol. 2025 Jul 30. doi: 10.1001/jamadermatol.2025.2567.
Abstract
摘要
相似文献
1
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.使用度普利尤单抗治疗抗体药物偶联物引起的皮肤毒性。
JAMA Dermatol. 2025 Jul 30. doi: 10.1001/jamadermatol.2025.2567.
2
Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.度普利尤单抗治疗大疱性类天疱疮有效性和安全性的真实世界评估：一项前瞻性队列多中心病例系列研究
Br J Dermatol. 2025 Feb 18;192(3):501-509. doi: 10.1093/bjd/ljae403.
3
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
4
Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.免疫肿瘤学
度普利尤单抗治疗与免疫检查点抑制剂相关的大疱性类天疱疮：一项回顾性病例系列研究。
Oncologist. 2025 Sep 1;30(9). doi: 10.1093/oncolo/oyaf208.
5
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
6
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.用于治疗肾移植受者急性排斥反应的多克隆抗体和单克隆抗体。
Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4.
7
Efficacy and safety of dupilumab in chronic hand eczema: a systematic review.度普利尤单抗治疗慢性手部湿疹的疗效与安全性：一项系统评价
Arch Dermatol Res. 2025 Feb 20;317(1):441. doi: 10.1007/s00403-025-03947-z.
8
Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study.度普利尤单抗治疗嗜酸性食管炎儿童：一项回顾性多中心研究。
BMC Pediatr. 2025 Feb 5;25(1):100. doi: 10.1186/s12887-024-05313-w.
9
Efficacy of Dupilumab in a Young Woman with Refractory Cutaneous Lichen Planus: A Case-Based Review.度普利尤单抗治疗难治性皮肤扁平苔藓年轻女性的疗效：基于病例的综述
Diseases. 2025 Jul 18;13(7):225. doi: 10.3390/diseases13070225.
10
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.针对嗜酸性粒细胞计数提示 2 型炎症的 COPD，应用度普利尤单抗。
N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21.
本文引用的文献
1
Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.恩诺单抗治疗相关皮肤反应作为生存和治疗反应的替代标志物
Int J Clin Oncol. 2025 Feb;30(2):267-276. doi: 10.1007/s10147-024-02672-3. Epub 2024 Dec 16.
2
Dermatologic toxicities of antibody-drug conjugates.抗体药物偶联物的皮肤毒性。
J Am Acad Dermatol. 2024 Dec;91(6):1177-1188. doi: 10.1016/j.jaad.2024.08.036. Epub 2024 Aug 23.
3
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.FDA 批准的抗体药物偶联物在人类癌症中的临床疗效评价。
Mol Cancer. 2024 Mar 23;23(1):62. doi: 10.1186/s12943-024-01963-7.
4
Management of immune-related cutaneous adverse events with dupilumab.度普利尤单抗治疗免疫相关皮肤不良反应的管理。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-007324.
5
Types of necroinflammation, the effect of cell death modalities on sterile inflammation.坏死性炎症的类型，细胞死亡方式对非感染性炎症的影响。
Cell Death Dis. 2022 May 2;13(5):423. doi: 10.1038/s41419-022-04883-w.
6
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells.含美登素的抗体药物偶联物在体外能选择性地诱导抗原阳性靶细胞产生免疫原性细胞死亡的特征。
Oncoimmunology. 2019 Jan 22;8(4):e1565859. doi: 10.1080/2162402X.2019.1565859. eCollection 2019.
Zotero 插件